Amino Acid PET to Assess the Efficacy of IDH Inhibitor Treatments for IDH Mutated Gliomas
NCT ID: NCT07017790
Last Updated: 2025-06-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
22 participants
OBSERVATIONAL
2025-06-30
2025-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Use of a Method "Radiomics" for DOPA PET in Gliomas
NCT06472440
Evaluation of the Use of Radiomics in 18F-FDOPA PET Examinations for the Characterization of Gliomas
NCT04469244
Amino Acid PET-based Response Assessment in IDH-mutant Gliomas (APPEAR)
NCT07159607
Contribution of Cerebral 18F-DOPA PET-CT Scan in High-grade Recurrent Gliomas
NCT04766632
PET (FDG)-MR Imaging for the Adult Patients Presented With Brain Tumor
NCT02071017
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amino-acid PET
Patients received 18-fluoroDopa then a PET exam
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Antoine VERGER
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHRU of NANCY
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025PI093
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.